[Local chemotherapy of bladder carcinoma with mitomycin (author's transl)].
40 patients with transitional cell carcinoma of the bladder, stage Tis, Ta und Tl, were treated by a topical cytostatica-therapy with Mitomycin C (MMC) after transurethral resection of the bladder in order to investigate: 1. The curative influence on the carcinoma in situ, 2. the prevention of tumor cell implantations. After an average observation time of up to the 23.4 months this concept of therapy seems to be promising because of clearly reduced recurrence rate and the lack of systemic toxicity. MMC absorption studies with 19 patients, partly with reflux and TUR-caused perforation of the bladder, showed that MMC instillation therapy (20 mg MMC in 40 ml NaCl) immediately after resection does not result inn systemically toxic serum concentration.
D000328:Adult; D000368:Aged; D002278:Carcinoma in Situ / Q000188:drug therapy; D006801:Humans; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage / Q000627:therapeutic use*; D009367:Neoplasm Staging; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
D008937:Mitomycins; D016685:Mitomycin
Lokale Chemotherapie des Harnblasenkarzinoms mit Mitomycin.